Human Leukocyte Antigen (HLA) and Vaccines

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Therapeutic Vaccines and Antibody Therapeutics".

Deadline for manuscript submissions: closed (31 January 2021) | Viewed by 4662

Special Issue Editors

Department of Neuroscience, Brain Sciences Center, University of Minnesota Medical School, Minneapolis, MN 55455, USA
Interests: human leukocyte antigen; vaccines against pathogens; vaccines against SARS-CoV-2; vaccines against cancer; human herpes and other viruses; cancer neoantigens
Special Issues, Collections and Topics in MDPI journals
Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN 55455, USA
Interests: cell biology and biochemistry; vaccines; gulf war illness; neurodegenerative diseases
Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN 55455, USA
Interests: Aging; Dementia; Human Leukocyte Antigen; PTSD; resilience
Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN 55455, USA
Interests: Bioinformatics; Vaccines; Human Leukocyte Antigen; Immunogenetics; Computational Biology

Special Issue Information

Dear Colleagues,

The success of vaccines in preventing illness depends on our ability to make antibodies against the pathogen components contained in the vaccines; if antibodies cannot be made, the vaccine will not be effective. In this case, vaccine antigens persist with the possibility of causing cell damage either directly or via molecular mimicry and autoimmunity. Now, the mounting of antibodies against specific antigens critically depends on the individual's Human Leukocyte Antigen (HLA) Class 2 genetic makeup, which consists of more than six alleles (two for each of the DRB1, DQB1, and DPB1 genes, plus the occasional DRB3, DRB4, and DRB5 allele). This Special Issue will focus on this matter, which is of major medical and public health importance but hardly covered elsewhere.

Prof. Apostolos P. Georgopoulos
Dr. Effie-Photini Tsilibary
Dr. Lisa M. James
Dr. Spyros Charonis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccines
  • persistent antigens
  • human leukocyte antigen
  • brain
  • neural cultures
  • antibodies

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 2636 KiB  
Article
Yeast-Based Aβ1-15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer’s Disease Transgenic Mice
by Dong-qun Liu, Shuai Lu, Lun Zhang, Ya-ru Huang, Mei Ji, Xiao-ying Sun, Xiao-ge Liu and Rui-tian Liu
Vaccines 2020, 8(3), 351; https://doi.org/10.3390/vaccines8030351 - 01 Jul 2020
Cited by 7 | Viewed by 3634
Abstract
Immunotherapy focusing on reducing the amyloid-beta (Aβ) burden is a promising treatment strategy for Alzheimer’s disease (AD). Many clinical studies on AD immunotherapies have failed due to low safety and efficacy, calling for a highly potent AD vaccine which induces sufficient antibody titer [...] Read more.
Immunotherapy focusing on reducing the amyloid-beta (Aβ) burden is a promising treatment strategy for Alzheimer’s disease (AD). Many clinical studies on AD immunotherapies have failed due to low safety and efficacy, calling for a highly potent AD vaccine which induces sufficient antibody titer while avoiding side effects. Here, we designed a yeast-based vaccine Y-5A15 comprising five copies of Aβ1-15 displayed on the surface of yeast cell wall, and we subcutaneously immunized APP/PS1 mice three times. Our results demonstrated that the Y-5A15 remarkably enhanced the Aβ epitope immunogenicity and elicited high antibody titers against Aβ in AD mice. Importantly, Y-5A15 vaccination successfully reduced Aβ levels, plaque burden and glial activation, rescued synaptic deficits and significantly ameliorated memory and cognitive decline in APP/PS1 transgenic mice, suggesting that the yeast-based Aβ epitope vaccine has a promising potency for the treatment of AD. Full article
(This article belongs to the Special Issue Human Leukocyte Antigen (HLA) and Vaccines)
Show Figures

Figure 1

Back to TopTop